Selective 5-HT2C Receptor Modulation

WAY163909 [(7b-R,10a-R)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta[b][1,4] diazepino [6,7,1hi]indole] was a gift from Pfizer, Inc. (New York, NY, United States) and was dissolved in 0.9% NaCl (vehicle, VEH). WAY163909 was tested at a dose range (0–2 mg/kg) that did not alter total horizontal ambulation in a motor activity monitor (3 mg/kg WAY163909 has been shown to significantly suppress total horizontal ambulation) but dose-dependently suppressed operant responding for self-administered sucrose pellets (Cunningham et al., 2011 (link)). These effects are completely blocked following pretreatment with the selective 5-HT_2CR antagonist SB242084 (Dunlop et al., 2005 (link); Cunningham et al., 2011 (link)). All injections were administered intraperitoneally (i.p.) in a volume of 1 ml/kg.